Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 93, Issue 7, 2012, Pages 744-749

  Stölzel, Friedrich ^a   Hackmann, Karl ^a   Kuithan, Friederike ^a   Mohr, Brigitte ^a   Füssel, Monika ^b   Oelschlägel, Uta ^a   Thiede, Christian ^a   Röllig, Christoph ^a   Platzbecker, Uwe ^a   Schetelig, Johannes ^a   Illmer, Thomas ^a   Schaich, Markus ^a   Seliger, Barbara ^c   Hartmann, Arndt ^d   Baretton, Gustavo ^a   Zietz, Christian ^a   Ehninger, Gerhard ^a   Schrock, Evelin ^a   Bornhäuser, Martin ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DKMS Life Science Lab GmbH   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Allogeneic; AML; Extramedullary; HLA loss

Indexed keywords

ANTINEOPLASTIC AGENT; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CELL SURFACE; CHROMOSOME 6P; CHROMOSOME LOSS; CLONAL EVOLUTION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FMS LIKE TYROSINE KINASE 3 GENE; GENE; GENE EXPRESSION; GENE LOCUS; GENE LOSS; GENE MUTATION; HAPLOTYPE; HLA B GENE; HLA C GENE; HLA E GENE; HLA J GENE; HUMAN; HUMAN LEUKOCYTE ANTIGEN GENE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; KARYOTYPE 46,XX; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I CHAIN RELATED GENE A; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I CHAIN RELATED GENE B; MULTIPLE CYCLE TREATMENT; NUCLEOPHOSMIN 1 GENE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TAP2 GENE;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; BIOPSY; BREAST NEOPLASMS; CLONAL EVOLUTION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; RISK ASSESSMENT; RISK FACTORS; SARCOMA, MYELOID; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84859265951     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182481113     Document Type: Article

References (17)

1. Thakar MS, Forman SJ. ASH evidence-based guidelines: Is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program 2009; 414
2. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675
3. Seliger B, Stoehr R, Handke D, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2010; 59: 529
4. Isoda T, Ford AM, Tomizawa D, et al. Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci USA 2009; 106: 17882
5. Murgia C, Pritchard JK, Kim SY, et al. Clonal origin and evolution of a transmissible cancer. Cell 2006; 126: 477
6. Siddle HV, Kreiss A, Eldridge MD, et al. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 2007; 104: 16221
7. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361: 478
8. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50
9. Platzbecker U, Thiede C, Fussel M, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707
10. Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2006; 47: 1754
11. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639
12. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935
13. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35
14. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820
15. Waterhouse M, Pfeifer D, Pantic M, et al. Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:1450
16. Villalobos IB, Takahashi Y, Akatsuka Y, et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 2010; 115: 3158
17. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011.